Clinical Trial Detail

NCT ID NCT03184558
Title BGB324 in Combination With Pembrolizumab in Patients With TNBC
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors BerGenBio ASA
Indications

triple-receptor negative breast cancer

Therapies

Bemcentinib + Pembrolizumab

Age Groups: senior adult

No variant requirements are available.